Ausgabe 3/2012
Special focus: neuroendocrine tumors. Part II
Inhalt (9 Artikel)
Targeting neuroendocrine tumor: mixing standard options with novel therapies
Eric Raymond, Chantal Dreyer, Sandrine Faivre
Place of surgical resection in the treatment strategy of gastrointestinal neuroendocrine tumors
Sébastien Gaujoux, Alain Sauvanet, Jacques Belghiti
Streptozocin-based chemotherapy is not history in neuroendocrine tumours
Katie Weatherstone, Tim Meyer
New treatment options with cytotoxic agents in neuroendocrine tumours
Pascal Hammel, Olivia Hentic, Cindy Neuzillet, Sandrine Faivre, Eric Raymond, Philippe Ruszniewski
Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies
Annemilaï Tijeras-Raballand, Cindy Neuzillet, Anne Couvelard, Maria Serova, Armand de Gramont, Pascal Hammel, Eric Raymond, Sandrine Faivre
Profiling mTOR pathway in neuroendocrine tumors
S. Cingarlini, M. Bonomi, V. Corbo, A. Scarpa, G. Tortora
Erratum to: Inhibition of mTOR in carcinoid tumors
Simona Grozinsky-Glasberg, Marianne Pavel
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma
Andres Morales La Madrid, Nicholas Campbell, Sonali Smith, Susan L. Cohn, Ravi Salgia